We know that a 5%-10% reduction in weight improves asthma, but patients with obesity still struggle with effectively managing their symptoms with current available treatments and experience more respiratory illnesses and complications, said Katherine Cahill, MD, Medical Director of Clinical Asthma Research and principal investigator of the study
Diabetologia 63 , 444447 (2020)
Read Article 23rd December 2025 Top 3 OTC Painkillers in The UK - Ashcroft Pharmacy Read Article 22nd December 2025 Diclofenac Sodium - Uses, Side Effects, and More - Ashcroft Pharmacy Read Article 19th December 2025 The Truth About NSAIDs: Safe Use for Pain Management Read Article 9th December 2025 Diclofenac Side Effects: Common and Serious Risks Explained Read Article 1st October 2025 Naproxen Dosage Guide: How Much to Take Safely Read Article 22nd September 2025 Naproxen Side Effects Made Simple: What Every Patient Should Know Read Article Ibuprofen 400mg Tablets Nurofen Plus Paracetamol 500mg Tablets Voltarol Max Strength Pain Relief 2.32% Gel Naproxen Gastro-Resistant Tablets (250mg & 500mg) Naproxen Tablets (250mg & 500mg) Solpadeine Max Diclofenac Sodium Tablets Written and reviewed by our qualified team Authored by: Mr Suhail Jamil Superintendent Pharmacist GPhC Number: 2069518 Order Monday to Friday before 14:00pm to guarantee next day delivery
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
, Helms, C
